R&D Insights: How Teva Pharmaceutical Industries Limited and Geron Corporation Allocate Funds

Teva vs. Geron: A Decade of R&D Investment Strategies

__timestampGeron CorporationTeva Pharmaceutical Industries Limited
Wednesday, January 1, 2014207070001488000000
Thursday, January 1, 2015178310001525000000
Friday, January 1, 2016180470002111000000
Sunday, January 1, 2017110330001848000000
Monday, January 1, 2018134320001213000000
Tuesday, January 1, 2019520720001010000000
Wednesday, January 1, 202051488000997000000
Friday, January 1, 202185727000967000000
Saturday, January 1, 202295518000838000000
Sunday, January 1, 2023125046000953000000
Monday, January 1, 2024998000000
Loading chart...

Unlocking the unknown

R&D Spending: A Tale of Two Companies

In the competitive world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Teva Pharmaceutical Industries Limited and Geron Corporation have taken distinct paths in their R&D investments.

Teva's Consistent Commitment

Teva has consistently allocated substantial resources to R&D, with an average annual expenditure of approximately $1.3 billion. Despite a slight decline in recent years, Teva's investment remains robust, underscoring its commitment to innovation.

Geron's Strategic Surge

In contrast, Geron Corporation has shown a remarkable increase in R&D spending, growing by over 500% from 2014 to 2023. This surge reflects Geron's strategic focus on advancing its pipeline, particularly in the field of oncology.

Conclusion

These contrasting strategies highlight the diverse approaches companies take in navigating the pharmaceutical landscape, each aiming to secure a competitive edge through innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025